Novartis Fights Samsung's Bid To Nix Syringe Patents

By Alex Baldwin (July 29, 2022, 4:38 PM BST) -- Novartis AG has fired back at an attempt by a Samsung biotech subsidiary to invalidate five of its syringe patents for being "uninventive," arguing that the challenge to its technology falls flat.

The Swiss company insisted that four of the patents challenged by Samsung Bioepis UK are valid in its defense filed at the High Court. But it says that the fifth was revoked by the European Patent Office in April 2021 so cannot be tried, according to the defense, filed July 21 and recently made public.

Samsung sued Novartis in June, claiming that the patents which cover filled syringes suitable...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!